Jefferies Group’s Charles River Laboratories CRL Stock Holding History

Jefferies Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$614K	Buy	+3,122	New	+$674K	0.01%	968
2021 Q3	–	Sell	-15,298	Closed	-$5.66M	–	1755
2021 Q2	$5.66M	Sell	15,298 -23,004	-60%	-$7.68M	0.04%	428
2021 Q1	$11.1M	Buy	38,302 +27,222	+246%	+$7.57M	0.1%	175
2020 Q4	$2.77M	Buy	11,080 +6,080	+122%	+$1.45M	0.02%	612
2020 Q3	$1.13M	Sell	5,000 -4,892	-49%	-$1.02M	0.01%	758
2020 Q2	$1.73K	Buy	+9,892	New	+$1.58M	0.02%	606
2019 Q2	–	Sell	-6,111	Closed	-$888K	–	2574
2019 Q1	$888K	Sell	6,111 -5,600	-48%	-$736K	0.01%	1325
2018 Q4	$1.32M	Buy	11,711 +6,799	+138%	+$851K	0.01%	1026
2018 Q3	$661K	Buy	4,912 +1,271	+35%	+$157K	﹤0.01%	1517
2018 Q2	$409K	Buy	+3,641	New	+$394K	﹤0.01%	1691
2018 Q1	–	Sell	-8,697	Closed	-$952K	–	2304
2017 Q4	$952K	Sell	8,697 -6,459	-43%	-$703K	﹤0.01%	1394
2017 Q3	$1.64M	Buy	15,156 +7,971	+111%	+$819K	0.01%	1035
2017 Q2	$727K	Sell	7,185 -11,597	-62%	-$1.07M	﹤0.01%	1440
2017 Q1	$1.69M	Buy	18,782 +4,798	+34%	+$408K	0.01%	1013
2016 Q4	$1.06M	Sell	13,984 -331	-2%	-$25.1K	0.01%	1240
2016 Q3	$1.19M	Buy	14,315 +8,859	+162%	+$743K	0.01%	1196
2016 Q2	$450K	Buy	+5,456	New	+$449K	﹤0.01%	1496
2016 Q1	–	Sell	-17,893	Closed	-$1.44M	–	2263
2015 Q4	$1.44M	Sell	17,893 -3,399	-16%	-$245K	0.01%	1014
2015 Q3	$1.35M	Buy	21,292 +20,628	+3,107%	+$1.48M	0.01%	1079
2015 Q2	$47K	Sell	664 -6,400	-91%	-$474K	﹤0.01%	2451
2015 Q1	$560K	Buy	7,064 +3,570	+102%	+$263K	﹤0.01%	1331
2014 Q4	$222K	Sell	3,494 -4,704	-57%	-$295K	﹤0.01%	1698
2014 Q3	$490K	Buy	8,198 +3,275	+67%	+$187K	﹤0.01%	1345
2014 Q2	$263K	Sell	4,923 -2,853	-37%	-$157K	﹤0.01%	1604
2014 Q1	$469K	Buy	7,776 +3,307	+74%	+$193K	﹤0.01%	1308
2013 Q4	$237K	Sell	4,469 -600	-12%	-$30.1K	﹤0.01%	1498
2013 Q3	$234K	Buy	+5,069	New	+$233K	﹤0.01%	1542

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Jefferies Group's CRL Position: Q3 2022 in Review

Jefferies Group opened a new position in Charles River Laboratories (CRL) in Q3 2022: 3,122 shares worth $614K. The stake represents 0.01% of the portfolio and ranks #968 among its holdings. This is a return to the name: Jefferies Group previously reported a position in CRL as recently as Q2 2021.

Jefferies Group first reported a position in CRL in Q3 2013 and has held it in 27 quarters since. The position peaked at $11.1M in Q1 2021. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

Jefferies Group held 3,122 shares of Charles River Laboratories worth $614K as of Q3 2022.
Charles River Laboratories was a new Jefferies Group position in Q3 2022.
Charles River Laboratories made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #968 holding.
Jefferies Group first reported a position in Charles River Laboratories in Q3 2013 and has held it in 27 quarters since.
Jefferies Group's Charles River Laboratories position peaked at $11.1M in Q1 2021.
583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.